|Quest Diagnostics Provides Update on Impact of Final 2018 Medicare Payment Rates for Clinical Laboratory Tests|
|SECAUCUS, N.J., Nov. 20, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today provided an update on the impact of the Centers for Medicare and Medicaid Services (CMS) publication of finalized 2018 Medicare reimbursement rates for clinical laboratory tests under the Clinical Lab Fee Schedule (CLFS) pursuant to the Protecting Access to Medicare Act (PAMA) announced November 17, 2017.
"We are... ||11/20/17|
|Quest Diagnostics to Present New Insights in Autoimmune Disease at the 2017 American College of Rheumatology Meeting|
|Five Presentations Show the Clinical Value of Diagnostic Innovations for Assessing Prevalent Autoimmune Diseases, Including Rheumatoid Arthritis and Lupus
Secaucus, NJ, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, announced today that it will present results of five studies at the 2017 American College of Rheumatology (ACR) Annual Meeting, November 3 – 8, 2017 in San Diego.
|Quest Diagnostics Acquires California Laboratory Associates|
|Transaction Expands Access to Innovative, High-Value Diagnostic Information Services in Southern California
SECAUCUS, N.J. and BURBANK, Calif., Oct. 30, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced it has acquired certain assets of California Laboratory Associates (CLA), a clinical lab network serving patients and providers in the Greater Los Angeles Area.
|Quest Diagnostics Reports Third Quarter 2017 Financial Results, Updates 2017 Financial Guidance and Reaffirms Long Term Outlook|
|- Third quarter revenues of $1.93 billion, up 2.4% versus 2016.
- Third quarter reported diluted EPS of $1.15, down 14.2% from 2016, which included an acquisition escrow recovery gain; and $1.39 on an adjusted basis excluding amortization, up 1.5% from 2016. Excess tax benefit associated with stock-based compensation benefited diluted EPS by $0.04 in the quarter and increased $0.02 compared to 2016.
- Updates outlook for full year 2017 primarily due to the financial impact of hurricanes an... ||10/19/17|